{
  "ticker": "OPL",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02961163",
  "id": "02961163",
  "pages": 37,
  "price_sensitive": false,
  "date": "20250623",
  "time": "1808",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250623/pdf/06l0tnbx7rc66q.pdf",
  "summary": "### **Material Information Summary \u2013 OPYL LIMITED (ASX: OPL)**  \n\n#### **General Meeting Overview**  \n- **Meeting Date/Time**: 25 July 2025, 10:30am (Sydney time).  \n- **Location**: 6 Middlemiss St, Milsons Point, NSW 2061.  \n\n---  \n\n### **Key Resolutions for Trading/Capital Markets Decisions**  \n\n1. **Ratification of Prior Share Issues**  \n   - **Resolution 1**: Ratification of 25,107,195 shares issued under ASX Listing Rule 7.1 (Placement, $0.021/share).  \n   - **Resolution 2**: Ratification of 16,892,805 shares issued under Listing Rule 7.1A (Placement, $0.021/share).  \n   - **Resolution 5**: Ratification of 500,000 shares issued to Peak Asset Management ($0.02/share).  \n\n2. **New Equity Issuances**  \n   - **Resolution 3**: Approval to issue **35,714,286 Placement Options** (1:1 ratio with Placement Shares, exercise price $0.03, 4-year expiry).  \n   - **Resolution 4**: Approval to issue **8,000,000 Broker Options** to Joint Lead Managers (Sandton Capital/GBA Capital) on same terms as Placement Options.  \n   - **Resolutions 7\u201310**: Conversion of loans into shares + options:  \n     - **Resolution 7**: 5,561,710 shares + 5,561,710 options ($0.015 exercise) to Irwin Biotech Nominees.  \n     - **Resolution 8**: 5,931,011 shares + 5,931,011 options ($0.015 exercise) to Maryton Australia.  \n     - **Resolution 9**: 12,671,469 shares + 12,671,469 options ($0.015 exercise) to Director Antanas Guoga (subject to related-party approval).  \n     - **Resolution 10**: 3,864,154 shares + 2,000,000 options ($0.025 exercise) to Irwin Biotech Nominees (separate loan).  \n\n3. **Incentive Securities**  \n   - **Resolution 11**: Issue **10,000,000 Performance Rights** to Director Saurabh Jain:  \n     - 3,333,333 vest on $100K+ TrialKey sales milestone.  \n     - 6,666,667 vest on CEO/CRO recruitment.  \n     - Expiry: 12 months from issue.  \n\n4. **Corporate Action**  \n   - **Resolution 6**: Change of company name to **Pathkey.AI Limited** (proposed ASX ticker: **PKY**).  \n\n---  \n\n### **Timetable/Dilution Impact**  \n- **If all resolutions pass**:  \n  - **Dilution**: Up to **~24.1% dilution** (undiluted to diluted basis) for major holders (e.g., Antanas Guoga\u2019s stake rises to 19.21% undiluted).  \n  - **Total potential new shares**: ~82M+ shares + 81M+ options/rights (excluding broker options).  \n\n- **Use of Funds**: Proceeds to fund AI drug discovery platform (TrialKey) and working capital.  \n\n---  \n\n### **Voting Exclusions**  \n- Votes from participating parties (e.g., Antanas Guoga, Saurabh Jain, Irwin Biotech, Maryton) excluded for relevant resolutions.  \n\n#### **Next Steps**  \n- **Proxy Deadline**: 23 July 2025, 10:30am.  \n- **Outcome Impact**: Failure to pass resolutions may require cash repayments (e.g., $83K to Irwin Biotech, $190K to Antanas Guoga).  \n\n---  \n**Final Note**: Focus on dilution, loan conversions, and director-linked issuances as primary valuation catalysts. Name change is non-material to fundamentals.  \n\n*No other material information identified.*",
  "usage": {
    "prompt_tokens": 28006,
    "completion_tokens": 848,
    "total_tokens": 28854,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-23T08:27:34.975040"
}